Improved Method for Detecting Mutant DNAs
Reported in a new study in The Journal of Molecular Diagnostics
Philadelphia, PA, October 11, 2011 – Molecular DNA testing methods offer clinicians powerful tools that serve to confirm or identify disease diagnoses. High sensitivity and high specificity, however, are frequently a challenge to achieve with these methods. In a study scheduled for publication in the November issue of The Journal of Molecular Diagnostics, researchers describe a new, robust technique that holds promise for identifying trace mutant DNA sequences (signals) in an overwhelming population of unmutated DNA (noise).
A group of researchers in Korea describe a simple and inexpensive enrichment technique that they have termed mutant enrichment with 3′-modified oligonucleotides (MEMO). This oligonucleotide blocks extension of the normal gene but enables extension of the mutated gene, allowing for increased detection sensitivity.
"The potential applications of MEMO include all situations in which minority alleles of clinical significance are present and sensitive detection is required,” commented lead investigators Seung-Tae Lee MD, PhD, and Chang-Seok Ki, MD, PhD, Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. “In addition to the application of MEMO to detect cancer mutations, it can be used in other situations, such as variant strain identification in infectious diseases (for example, the YMDD mutation in hepatitis B virus infection and antiviral drug–resistant variants in human immunodeficiency virus infection), minor mutant allele detection in patients with low-level somatic mosaicism or mitochondrial heteroplasmy, and characterization of fetal mutations from maternal plasma samples."
Using genomic DNA extracted from cancer-derived cell lines containing EGFR, BRAF, JAK2, TP53, or KRAS mutations and from a bone marrow sample containing an NPM1 mutation, the authors were able to demonstrate significant sensitivity to these mutations.
Compared to preexisting methods, MEMO was shown to provide an improved diagnostic performance so that the method can be easily applicable in various medical fields, where molecular assays are important for disease diagnosis or treatment monitoring, and thus may help to improve patient outcomes.
The article is “Mutant Enrichment with 3′-Modified Oligonucleotides (MEMO) - A Practical PCR Method for Detecting Trace Mutant DNAs” by Seung-Tae Lee, Ji-Youn Kim, Min-Jung Kown, Sun Wook Kim, Jae Hoon Chung, Myung-Ju Ahn, Young Lyun Oh, Jong-Won Kim, and Chang-Seok Ki (doi: 10.1016/j.jmoldx.2011.07.003). Published online ahead of its issue, it will appear in The Journal of Molecular Diagnostics, Volume 13, Issue 6 (November 2011) published by Elsevier.
# # #
Notes for editors
Full text of the article is available to credentialed journalists upon request; contact David Sampson at 215-239-3171 firstname.lastname@example.org. Journalists wishing to interview the authors may contact Dr. Chang-Seok Ki at email@example.com.
About The Journal of Molecular Diagnostics
The Journal of Molecular Diagnostics, ( jmd.amjpathol.org), the official publication of the Association for Molecular Pathology, co-published by the American Society for Investigative Pathology, seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome for review articles that contain: novel discoveries or clinicopathologic correlations including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods for diagnosis or monitoring of disease or disease predisposition.
The Journal of Molecular Diagnostics, with an Impact Factor of 4.219, ranks among the Top 10 journals in Pathology, according to Thomson Reuters Journal Citation Reports® 2010.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Executive Publisher, Elsevier
+1 215 239 3171
Dr. Audra Cox
The American Journal of Pathology
+1 301 634 7409